Results
A total of 372 patients received a 10-μg bimatoprost implant on day 1 of the ARTEMIS studies. Biodegradation of the implants was evaluated on gonioscopy and analyzed for all patients who had an implant size assessment at week 2 (Distribution of implant size by time after administration. Patients were administered a 10-μg bimatoprost implant on day 1 in the ARTEMIS studies. During gonioscopic examination at follow-up visits, the size of the implant was estimated and categorized by percent initial size. Results shown are based on observed values (During the initial phase of biodegradation from 2 to 28 weeks, implants were often reported to swell (Time course of the biodegradation of the implant. Results shown are based on observed values (Accelerated biodegradation occurred between 31 and 52 weeks, with most implants showing clinically significant biodegradation during this period. At week 52, 82.1% (165/201) of implants were reported to be absent or ≤25% of their initial size, 92.0% (185/201) were reported to be ≤50% of their initial size, and 95.5% (192/201) were reported to be ≤75% of their initial size (Gonioscopic examinations also included assessment of the implant location. The implant typically settled in the inferior iridocorneal angle. At each visit through week 15, ≥72.5% (258/356) of visible implants were located in Zone 6, inferiorly in the iridocorneal angle, and ≥96.0% (332/346) were located in Zone 5, 6, or 7 inferiorly (Implant location in the iridocorneal angle.